Mar 11, 2022, 14:09 PM by

CD ComputaBio, a reliable computational biology service provider located in New York, always hammers at researches and trials in order to provide customers with access to the latest software, technologies, and expertise at a competitive price and fast turnaround time. Recently, the product manager announced the launch of molecular docking service, which has a wide range of applications in the field of enzymology research and drug design.

Mar 11, 2022, 14:09 PM by

Mar 11, 2022, 14:09 PM by

Firstsource Solutions Limited, a global provider of Business Process Management (BPM) services and an RP-Sanjiv Goenka Group company, was ranked #1 in the 2022 Best in KLAS®: Software & Services Report, and noted as a leader in the Eligibility and Enrollment Services category.

Mar 11, 2022, 14:09 PM by

Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy

Mar 11, 2022, 14:09 PM by

A research team led by Samuel Beck, Ph.D., of the MDI Biological Laboratory in Bar Harbor, Maine, has identified disruption of chromatin architecture as the mechanism underlying inflammaging, a chronic, low-grade inflammatory response that has been linked to the chronic diseases of old age, including Alzheimer’s, cancer, diabetes, heart disease, macular degeneration and more, as well as to a shortened lifespan.

Mar 11, 2022, 14:09 PM by

Rho, a global full-service contract research organization (CRO), is sharing its drug development success and expertise in gene therapy research during the 5th Annual Gene Therapy for Rare Disorders Conference, taking place in Boston, Massachusetts from March 7-10. Rho’s Associate Director of Regulatory Strategy, Joseph Watson, Senior Director of Nonclinical Development, Brenda Faiola, and Research Scientist Kelsey Behrens will be giving a presentation titled, “Nonclinical Considerations to Enable a Successful Clinical Program.” The March 9 presentation at 2:00 p.m. will discuss key design and execution components, for nonclinical studies, necessary to enable clinical studies. The following items will be addressed: ü Considerations for gene therapy programs regarding animal models, dose selection, and delivery device compatibility ü Lessons Rho has learned in interacting with the FDA across various gene therapy programs ü Gene therapy approval examples that highlight key nonclinical considerations

Mar 11, 2022, 14:09 PM by

Mar 11, 2022, 14:09 PM by

Mar 11, 2022, 14:08 PM by

Mar 11, 2022, 14:08 PM by

Creative Biogene has become the premier partner to cooperate in the exploration of the pathogenesis of mitochondrial-associated diseases.

Mar 11, 2022, 14:08 PM by

Mar 11, 2022, 14:08 PM by

Pronalyse, a new division of Creative Proteomics, is an integrated CRO company with rich experience in providing drug development services for over 10 years. Creative Proteomics Pronalyse recently announced the launch of antibody-drug conjugates (ADCs) characterization service to ensure the safety and effectiveness of ADCs drugs.

Mar 11, 2022, 14:08 PM by

As a division of Creative Proteomics, Lipidomics is dedicated to providing cutting-edge mass spectrometry (MS)-based lipidomics services for biomedical research institutions, biotechnological and pharmaceutical companies. The company has recently announced the launch of fully-developed lipidomics bioinformation analysis service to screen differential lipid molecules and analyze their pathways, revealing the physiological mechanism of their changes.

Mar 11, 2022, 14:08 PM by

Metabolomics, a division of Creative Proteomics, is dedicated to providing cutting-edge LC-MS based metabolomics services for biomedical research institutions, biotechnology and pharmaceutical companies. With deep industry and business process expertise and a good reputation in providing contract services specialized for metabolomics, Creative Proteomics Metabolomics announced the launch of microbial metabolomics service to promote a comprehensive understanding of microbial physiology.

Mar 11, 2022, 14:08 PM by

PhenoTips, producer of the leading software solution for medical genetics, is proud to announce the pledge of 1% of their equity to The Upside Foundation of Canada in support of CHEO Foundation, SickKids Foundation, and the Canadian Organization of Rare Disorders (CORD).

Mar 11, 2022, 14:08 PM by

ERGOMED announces launch of its Rare Disease Innovation Center™ Rare Disease Innovation Center to provide strategic guidance and tailored innovative solutions to sponsors focused on rare disease drug development Raleigh, North Carolina, February 28, 2022 – ERGOMED plc (LSE: ERGO) a leading Clinical Research Organization focused on rare disease drug development today announced the establishment of its Rare Disease Innovation Center.

Mar 11, 2022, 14:08 PM by

mdgroup to partner with ERGOMED on new Rare Disease Innovation Center Collaboration will provide sponsors with access to industry-leading technology and expertise to optimise rare disease drug development and tackle unmet medical need. Bracknell, UK: 28 February 2022 – mdgroup, the leading global provider of personalised clinical study services and technologies, has been selected to provide patient support services to Ergomed’s Rare Disease Innovation Centre.

Mar 11, 2022, 14:08 PM by

Research Triangle Park, NC – February 28, 2022 – Rho, a global, full-service contract research organization (CRO) with a proven track record of drug development success, today announced that it has been named the Autoimmune Diseases Statistical and Clinical Coordinating Center (AD-SCCC) for the National Institute of Allergy and Infectious Diseases. As the AD-SCCC, Rho will provide a broad range of services critical for the design, development, execution, and analysis of clinical research in autoimmune diseases. This project has been funded $8.3 million in the first year with Federal funds from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93022C00003. This award has the potential to provide a total of over $49 million to the AD-SCCC over the next five years.

Mar 11, 2022, 14:08 PM by

AccessDx Laboratory, a global provider of advanced laboratory diagnostics solutions, has introduced an expanded pharmacogenomics (PGx) test that improves the quality, availability and actionability of drug-gene insights within the clinical workflow. The AccessDx PGx Profile is designed to help providers identify potential risks for adverse drug reactions or reduced medication efficacy.

Mar 11, 2022, 14:08 PM by

VERICHEM offers clinical laboratories their liquid stable and ready-to-use MATRIX PLUS™ Chemistry Reference Materials which are expressly designed for the calibration and calibration verification of chemistry assays and to support overall system QC and CLIA compliance.